Literature DB >> 12460560

BDNF regulates the expression of fragile X mental retardation protein mRNA in the hippocampus.

Maija Castrén1, Katariina E Lampinen, Riitta Miettinen, Eija Koponen, Ilkka Sipola, Cathy E Bakker, Ben A Oostra, Eero Castrén.   

Abstract

Both fragile X mental retardation protein (FMRP) and brain-derived neurotrophic factor (BDNF) are implicated in the maturation of neurons and in the higher cognitive functions. We have investigated whether FMRP and BDNF are reciprocally regulated in neurons. Exposure of cultured hippocampal neurons to BDNF, but not to NT-3, reduced FMR1 mRNA levels to 84.8% of control at 4 h and the levels were back to baseline by 24 h or 4 days. Furthermore, expression of FMR1 mRNA was reduced (82.4% of control) in vivo in the hippocampus of transgenic mice overexpressing TrkB receptors, and a small but significant (5.1%) decrease was also detected in FMRP protein levels. In contrast, the expression patterns of BDNF and TrkB mRNAs were not altered in FMRP-deficient mice compared to wild-type mice. Our data provide evidence that BDNF via TrkB signaling decreases FMRP expression and suggest a role for FMRP in BDNF-induced synaptic plasticity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12460560     DOI: 10.1006/nbdi.2002.0544

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  18 in total

Review 1.  Secreted factors as synaptic organizers.

Authors:  Erin M Johnson-Venkatesh; Hisashi Umemori
Journal:  Eur J Neurosci       Date:  2010-07-14       Impact factor: 3.386

2.  Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome.

Authors:  Craig A Erickson; Logan K Wink; Balmiki Ray; Maureen C Early; Elizabeth Stiegelmeyer; Lauren Mathieu-Frasier; Vanessa Patrick; Debomoy K Lahiri; Christopher J McDougle
Journal:  Psychopharmacology (Berl)       Date:  2013-02-24       Impact factor: 4.530

3.  Major defects in neocortical GABAergic inhibitory circuits in mice lacking the fragile X mental retardation protein.

Authors:  Leah Selby; Chunzhao Zhang; Qian-Quan Sun
Journal:  Neurosci Lett       Date:  2006-12-15       Impact factor: 3.046

Review 4.  Serotonin dysregulation in Fragile X Syndrome: implications for treatment.

Authors:  Alicia C Hanson; Randi J Hagerman
Journal:  Intractable Rare Dis Res       Date:  2014-11

Review 5.  Transcript specificity in BDNF-regulated protein synthesis.

Authors:  Claudia R Ruiz; Jay Shi; Mollie K Meffert
Journal:  Neuropharmacology       Date:  2013-05-22       Impact factor: 5.250

6.  Frontostriatal deficits in fragile X syndrome: relation to FMR1 gene expression.

Authors:  V Menon; J Leroux; C D White; A L Reiss
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-01       Impact factor: 11.205

Review 7.  RNA-binding proteins, neural development and the addictions.

Authors:  C D Bryant; N Yazdani
Journal:  Genes Brain Behav       Date:  2016-01       Impact factor: 3.449

8.  Brain derived neurotrophic factor and serotonin transporter binding as markers of clinical response to fluoxetine therapy in children with autism.

Authors:  Ismo Makkonen; Raili Riikonen; Jyrki T Kuikka; Hannu Kokki; Joseph P Bressler; Cathleen Marshall; Walter E Kaufmann
Journal:  J Pediatr Neurol       Date:  2011-03

9.  Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice.

Authors:  Aditi Bhattacharya; Hanoch Kaphzan; Amanda C Alvarez-Dieppa; Jaclyn P Murphy; Philippe Pierre; Eric Klann
Journal:  Neuron       Date:  2012-10-17       Impact factor: 17.173

10.  Critical period plasticity is disrupted in the barrel cortex of FMR1 knockout mice.

Authors:  Emily G Harlow; Sally M Till; Theron A Russell; Lasani S Wijetunge; Peter Kind; Anis Contractor
Journal:  Neuron       Date:  2010-02-11       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.